News

APG101 is a fully-human fusion protein that inhibits the CD95 ligand, a member of the tumor necrosis factor (TNF) family. It isindicated to treat glioblastoma multiforme in China,

As part of the deal, Laboratorios Saval will be responsible to secure regulatory and pricing approval as well as provide marketing and distribution of the product in Bolivia,

As part of the deal, both the parties will carry out studies designed to improve the mechanistic understanding of fibrosis, explore patient segmentation based on disease characteristics and/or

The study, which is open for enrollment, is titled "A Phase 1 exploratory study of the safety and ex vivo fluorescence of BLZ-100 administered by intravenous injection in

A rolling submission is intended to accelerate the review process by enabling review of portions of the NDA by the FDA prior to submission of the complete application.

The intellectual property was developed at the Henry Ford Hospital System, Detroit, Michigan, by Drs. Michael Chopp, Daniel Morris, and Zhenggang Zhang, and in-licensed by RegeneRx Biopharmaceuticals, Inc.

Cara’s formulation of oral CR845 will continue to utilize Enteris’ proprietary oral delivery technology under a renewed and revised Manufacturing and Clinical Supply Agreement. The new agreement includes

VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery. Viking intends to commence

Rett syndrome primarily affects females with an estimated prevalence ranging from one in 10,000 to 20,000 females and there are no approved treatments available. In preclinical testing with